This article was originally published in The Rose Sheet
Executive SummaryFrench skin-care line Lierac Paris continues to expand to CVS doors throughout northeast U.S., pharmacy chain announces April 8. Line will be sold in 528 CVS stores in New York metro area, Boston and Washington, D.C. by April 30. CVS "strives to enhance the beauty shopping experience for our customers, and offering a high-quality, high-performance band like Lierac Paris at 528 locations nationwide is just one example of how we are achieving this," says Cheryl Mahoney, VP-merchandising/beauty care for CVS. Lierac's "medical approach is sure to appeal to a clientele that is accustomed to making cosmetic purchases in a pharmacy setting," CVS says. Retail prices range from $23 to $65...
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.